Novel Compounds May Battle Disease... ( Rodent trials suggest they could prot...)

Novel Compounds May Battle Diseases of Aging

Date:11/28/2007

Rodent trials suggest they could protect against type 2 diabetes

WEDNESDAY, Nov. 28 (HealthDay News) -- Experimental compounds aimed at treating diseases such as type 2 diabetes show promise, scientists say.

These "novel chemical entities" activate SIRT1, a gene controlling the aging process, the researchers report in the Nov. 29 issue of Nature.

In obese mice, these compounds improved insulin sensitivity, lowered plasma glucose levels, and increased the function of mitochondria (the powerhouse of cells).

In rats, the compounds improved whole body glucose homeostasis and insulin sensitivity in fat tissue, skeletal muscle, and the liver.

The experimental compounds were developed and tested by Sirtris Pharmaceuticals Inc., in Cambridge, Mass.

"The new drug candidates represent a significant milestone because they are the first molecules that have been designed to act on genes that control the aging process. For this reason, we feel they have considerable potential to treat diseases of aging such as Type 2 diabetes," Dr. Cristoph Westphal, chief executive officer and vice chair of Sirtris Pharmaceuticals, said in a prepared statement.

He said the results from the rodent tests highlight the potential of these new compounds to treat aging-related diseases, and the company hopes to begin human studies of one of the compounds in the first half of 2008.

More information

The U.S. Centers for Disease Control and Prevention looks at healthy aging.

-- Robert Preidt

SOURCE: Sirtris Pharmaceuticals Inc., news release, Nov. 28, 2007

0

GOOD

Post Your Comments:

(Date:1/8/2009)..., study suggests , , THURSDAY, Jan. 8 (...rongly they would react to racist acts, a new Cana...y participants at York University, in Toronto, sti... person rather than a black one, even after their ...rson when he left the room. , "And the racist...

(Date:1/8/2009).../ -- Allscripts-Misys Healthcare,Solutions, Inc.,...llscripts or,the Company), today announced its fi...d November 30, 2008. , (Logo: http://www.n...) , The Company,s results for the three and...ts from legacy Allscripts for the period of Octobe...

(Date:1/8/2009)...wire/ -- A new educational Web site offers expert ...ical products and medical devices from the Agency ...Education and Research on Therapeutics (CERTs), a ...eading research centers nationwide. The Clinician...AIN ) http://www.chainonline.org links clinician...

(Date:1/8/2009)...Call/ -- Heska Corporation (Nasdaq: HSKA ) annou... Heska Corporation Invites You to Join Its Fourth... Conference Call on the Web, When: Monda... www.heska.com (click on the Q4 and Year-End 200...age of this website)., How: Live over t...

[0] Many Turn Blind Eye to Racism [0] Allscripts Reports Fiscal 2009 Second Quarter Results [0] AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics [0] Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast

...esearchers say eating fish could help keep ones mi... high intake of cholesterol and saturated fat have...middle age. More and more research is showing what... for dementia. For example, studies have shown tha...

... risk factor, which accounts for about half of the...e is now a more dependable, less expensive test to... the NMP22 tumor marker assay in 1,331 patients at...s found that of the 79 patients shown to have blad...

...ound in the air in many inner-city homes could be ...n children say researchers. According to researche...ously exposed to the allergy-causing substance fou... the air and exposure increases their risk for dev...

...sted early onset wheezing is associated with high ...d bronchial hyper-responsiveness. Children with th... more severe asthma. However, some children who de...ith the same characteristics as those who begin wh...

Other Medicine News:

Consumption Of Fish Could Reduce The Risk Of Dementia More Dependable Screening Test For Bladder Cancer Mouse Allergen Found In Homes Could Trigger Asthma In Kids Childhood Wheezing Could Be Hereditary

(Date:1/7/2009)... ImQuest Life Sciences announced today the success...nd Drug Administration to initiate human clinical ...r IQP-0410. ImQuest anticipates initiating their P...410 is a novel small molecule inhibitor of HIV whi...criptase inhibitor (NNRTI). The compound possesses...

(Date:1/6/2009)...from prior U.S., U.K. and China Trials , , SAN .... (VTI), a development stage company targeting liv... begun for a randomized, controlled, multi-center,...orporeal Liver Assist Device (ELAD) as a treatment... three protocols. The study is open for enrollment...

(Date:1/6/2009)...ewswire/ -- Sequella, Inc., a clinical-stage bioph...ic potential, announced today that SQ109, its lead...(TB), was the first drug approved for evaluation i...port Vaccine Company LLC and Quintiles Transnation...e of Allergy and Infectious Diseases (NIAID), Nati...

(Date:1/5/2009)...ne Pharmaceuticals announced today that it has ini...otein kinase inhibitor, CX-4945, in patients with ...tiple myeloma. The primary endpoints of the oral d...tolerance and PK properties of CX-4945 and to sele...dition, multiple mechanism-related pharmacodynamic...

Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2 ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2 ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3 Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2 Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3 Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2 Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3 PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 1 PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 2 PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 3 PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 4 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 1 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 2 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 3 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 4 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 5 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 6 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 7 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 8 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 9 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 10 China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 11 Sentillion Appoints New UK Sales Manager 30669 1 Sentillion Appoints New UK Sales Manager 30669 2 Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 1 Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 2 Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 3 Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 4

[0] ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 [0] ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers [0] Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program [3] Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

...gress of European Hematology,Association (EHA) -, ...ll/ --,Immunomedics, Inc. , a biopharmaceutical co...to treat cancer and other serious,diseases, today ...,of EHA in Vienna, Austria, showed positive respon...treated with a new,radioimmunotherapy (RAIT) using...

...--Jun 11, 2007 - Geron,Corporation (Nasdaq:GERN) t...s indicating that GRNOPC1, the company,s human,emb...treatment of,spinal cord injury, evades a direct a...ron scientist Ross Okamura at the Federation of,Cl...the findings,could mean that patients treated with...

Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2 Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3 Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4 Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5 Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2 Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System

...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...

Medicine Products:

Allergens, Inhalants, Midwest Comprehensive 2 Allergens, Inhalants, Environmental Profile 10 Allergens, Inhalants, Comprehensive Profile Allergens, Inhalants, California Environmental

Novel Compounds May Battle Disease...( Rodent trials suggest they could prot...),Health